| 产品描述: | Tofogliflozin (CSG 452) 是一种新型的sodium-glucose co-transporter 2(SGLT2)抑制剂,对hSGLT2和hSGLT1的IC50值分别为2.9 nM和8444 nM |
| 靶点: |
hSGLT2(Cell-free assay):2.9 nM;SGLT; ReactiveOxygenSpecies; ROS |
| 体外研究: |
Tofogliflozin是一种有效的、选择性的SGLT2抑制剂,其对SGLT2的选择性是对SGLT1的2900倍。Tofogliflozin可浓度依赖性地抑制葡萄糖进入小管上皮细胞。tofogliflozin抑制高糖诱导的ROS产生,MCP-1能够诱导小管上皮细胞的凋亡,诱导NAC抗氧化 |
| 体内研究: |
单药口服给药在Zucker糖尿病大鼠中能够降低血糖水平,增加生脏葡萄糖清除率。用Tofogliflozin连续处理4周,能够显著地改善db/db小鼠的葡萄糖耐受性。而losartan没有次效果。Tofoglifozin的处理可减少db/db小鼠中的葡萄糖重吸收阈值,增加UGE、减少PG;Tofogliflozin的处理可显著地、剂量依赖性地提升总的beta细胞数量。说明阻止了beta细胞的降低。Tofogliflozin抑制血浆中葡萄糖和糖化的Hb、维持胰脏beta细胞的质量和血浆胰岛素水平 |
| 细胞实验: |
Cell lines: 小管上皮细胞 Concentrations: 3 nM 或 30 nM Incubation Time: 24 h Method: 用3 nM或30 nM的tofogliflozin处理小管上皮细胞(无血清的、含10 μg/ml transferrin和GA-1000的BM培养基),37℃下处理24小时。然后用PBS洗涤细胞,将细胞置于含100 μM 2-NBDG的HBSS溶液中孵育15 min。然后移除培养基,换乘纯HBSS溶液,检测细胞中的荧光强度 |
| 动物实验: |
Animal Models: db/db mice Dosages: 0.005 or 0.015% Administration: oral |
| 参考文献: |
1. Yoshihito Ohtake, et al. Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. J Med Chem. 2012, 55(17):7828-7840. 2. Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013, 170(3):519-31. 3. Ishibashi Y, et al. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation. Horm Metab Res. 2016, 48(3):191-5. |
| 溶解性: |
Soluble in DMSO、H2O、Ethanol |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.472 ml |
12.362 ml |
24.725 ml |
| 5 mM |
0.494 ml |
2.472 ml |
4.945 ml |
| 10 mM |
0.247 ml |
1.236 ml |
2.472 ml |
| 50 mM |
0.049 ml |
0.247 ml |
0.494 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |